SG11201901993SA - Use of recombinant lymphocyte activation gene-3 - Google Patents

Use of recombinant lymphocyte activation gene-3

Info

Publication number
SG11201901993SA
SG11201901993SA SG11201901993SA SG11201901993SA SG11201901993SA SG 11201901993S A SG11201901993S A SG 11201901993SA SG 11201901993S A SG11201901993S A SG 11201901993SA SG 11201901993S A SG11201901993S A SG 11201901993SA SG 11201901993S A SG11201901993S A SG 11201901993SA
Authority
SG
Singapore
Prior art keywords
international
lag3
risk
lymphocyte activation
recombinant
Prior art date
Application number
SG11201901993SA
Inventor
Oquendo Annabelle Rodriguez
Original Assignee
Oquendo Annabelle Rodriguez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oquendo Annabelle Rodriguez filed Critical Oquendo Annabelle Rodriguez
Publication of SG11201901993SA publication Critical patent/SG11201901993SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property :::` , Organization MD 1101111 0 DOI HIM 011101 0 011111111111111111111111111111111111111111111 International Bureau (10) International Publication Number 03 (43) International Publication Date .....•\"\" WO 2018/049410 Al 15 March 2018 (15.03.2018) WIP0 I PCT (51) International Patent Classification: G01N 33/92 (2006.01) Published: — with international search report (Art. 2 1 (3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US2017/051210 claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) 12 September 2017 (12.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/262,618 12 September 2016 (12.09.2016) US (72) Inventor; and (71) Applicant: RODRIGUEZ OQUENDO, Annabelle [US/US]; 79 Bradford Walk, Farmington, CT 06032 (US). (74) Agent: CRAIG, Royal, W.; Baker, Donelson, Beaman, Caldwell & Berkowitz, PC, 100 Light Street, 19th Floor, Baltimore, MD 21202 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = (84) 1-1 ..! (54) Title: USE OF RECOMBINANT LYMPHOCYTE ACTIVATION GENE-3 0 (57) : A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular 1-1 iv and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein defl- Of ciency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG3 mimetic as a companion therapeutic alone 71' or in combination with a statin and/or an anti-hyperlipidemic drug, The risk assessment is two-prong, beginning with a qualitative de- 0 --.... termination whether a subject has of is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or 0 1-1 0 to dysfunctional HDL, followed, by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the O LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic ei use of a cholesterol mediating, drug for treatment. C
SG11201901993SA 2015-09-16 2017-09-12 Use of recombinant lymphocyte activation gene-3 SG11201901993SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219429P 2015-09-16 2015-09-16
US15/262,618 US10265379B2 (en) 2015-09-16 2016-09-12 Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
PCT/US2017/051210 WO2018049410A1 (en) 2015-09-16 2017-09-12 Use of recombinant lymphocyte activation gene-3

Publications (1)

Publication Number Publication Date
SG11201901993SA true SG11201901993SA (en) 2019-04-29

Family

ID=60157173

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901993SA SG11201901993SA (en) 2015-09-16 2017-09-12 Use of recombinant lymphocyte activation gene-3

Country Status (12)

Country Link
US (2) US10265379B2 (en)
EP (1) EP3510410A4 (en)
JP (1) JP2019534318A (en)
KR (2) KR20210043011A (en)
CN (1) CN109716139A (en)
AU (2) AU2017322742A1 (en)
BR (1) BR112019004703A2 (en)
CA (1) CA3036090A1 (en)
IL (1) IL265258A (en)
MX (1) MX2019002821A (en)
SG (1) SG11201901993SA (en)
WO (1) WO2018049410A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265379B2 (en) * 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
WO2018165574A1 (en) * 2017-03-10 2018-09-13 The Regents Of The University Of California Method for diagnosing risk for inflammatory disease through glycan profiling

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US9995759B2 (en) * 2012-12-06 2018-06-12 Annabelle Rodriguez Oquendo Use of lymphocyte activation gene 3 (LAG-3) expression profiling as a biomarker for assessing inflammasomes, chronic inflammatory diseases and dysfunctional HDL
UY35468A (en) * 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
GB201322626D0 (en) * 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
US10265379B2 (en) * 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases

Also Published As

Publication number Publication date
US10265379B2 (en) 2019-04-23
US20170312338A1 (en) 2017-11-02
EP3510410A4 (en) 2020-03-25
US20190365855A1 (en) 2019-12-05
KR20190049844A (en) 2019-05-09
KR20210043011A (en) 2021-04-20
US10751388B2 (en) 2020-08-25
CN109716139A (en) 2019-05-03
WO2018049410A1 (en) 2018-03-15
CA3036090A1 (en) 2018-03-15
MX2019002821A (en) 2019-09-19
IL265258A (en) 2019-05-30
EP3510410A1 (en) 2019-07-17
AU2017322742A1 (en) 2019-03-28
AU2023282264A1 (en) 2024-01-18
JP2019534318A (en) 2019-11-28
BR112019004703A2 (en) 2019-05-28

Similar Documents

Publication Publication Date Title
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201900677SA (en) Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201908090VA (en) Biomonitoring devices, methods, and systems for use in a bathroom setting
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201810076WA (en) Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
SG11201908787WA (en) Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
SG11201804178YA (en) Pd1 and/or lag3 binders
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201909652WA (en) Neoantigen identification, manufacture, and use
SG11201909344SA (en) Anti-lag3 antibodies
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201903946SA (en) Devices and methods for slurry generation
SG11201808196UA (en) Neoantigens and methods of their use
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201903889TA (en) Crenolanib for treating flt3 mutated proliferative disorders associated mutations
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201806282XA (en) High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
SG11201806401YA (en) G protein-coupled receptor (gpcr) modulation by imipridones
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof